Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain
Revista Española de Sanidad Penitenciaria · 2024
DOI: 10.18176/resp.00095 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Revista Española de Sanidad Penitenciaria, 2024. Verfasst von Juan Turnes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Department. CHU. Pontevedra. Spain. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
Direct-acting antivirals (DAAs) share pharmacokinetic pathways with many comedications commonly administered to patients living with chronic hepatitis C virus (HCV) infection (PLWHCV). International guidelines recommend a thorough drug-drug interaction (DDI) risk assessment prior to starting DAA therapy and before starting comedications. This study aims to evaluate the impact of potential multiple DDIs in the real-life adverse event (AE) profile of PLWHCV treated with DAAs. Material and method: This is a retrospective, observational study using electronic medical records. Patients included were PLWHCV and were treated with either the protease inhibitor (PI) free DAA sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB) between 2017 and 2020. Potential (single and multiple) DDIs were identified using the Liverpool HEP Interaction Checker. AEs potentially associated to DDIs were identified during DAA treatment period.
Results
1620 patients with DAA prescriptions (SOF/VEL or GLE/PIB) were included. Of these, 123 were predicted to have multiple DDIs (multi-DDI). About 10% (123/1256) of the patients receiving ≥2 comedications were at risk of multi-DDI with DAA. Most comedication-associated AEs were recorded in this multi-DDI population (88.9%, 16/18), meaning that 13% (16/123) of the multi-DDI population suffered AEs. According to DAA regimen, more comedication-associated AEs were reported in GLE/PIB-treated as compared with SOF/VEL-treated patients (18.3% [13/71] vs 5.8% [3/52] p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Department. CHU. Pontevedra. Spain.
- Digestive Medicine Department. Hospital Marina Baixa de Villajoyosa (Alicante). Spain.
- Hospital Pharmacy. Hospital de Valme. AGS Sur de Sevilla. Spain.
- Medical Affairs. Gilead Sciences S.L. Madrid. Spain.
- Global Medical Affairs. Gilead Sciences Europe Ltd. U.K.
- Health Economics and Outcomes Research. Atrys Health. Barcelona. Spain.
Zitieren
APA
Turnes, J., García-Herola, A., Morillo-Verdugo, R., Méndez, M., Hernández, C., & Sicras-Mainar, A. (2024). Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain. Revista Española de Sanidad Penitenciaria. https://doi.org/10.18176/resp.00095
Vancouver
Turnes J, García-Herola A, Morillo-Verdugo R, Méndez M, Hernández C, Sicras-Mainar A. Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain. Revista Española de Sanidad Penitenciaria. 2024. doi:10.18176/resp.00095
BibTeX
@article{Turnes2024,
author = {Turnes, Juan and García-Herola, Antonio and Morillo-Verdugo, Ramón and Méndez, Marinela and Hernández, Cándido and Sicras-Mainar, Antoni},
title = {Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain},
journal = {Revista Española de Sanidad Penitenciaria},
year = {2024},
doi = {10.18176/resp.00095}
}
EUVIMED